NUTX Nutex Health Inc. Insider Trading

Director Frank E Jaumot buys 150 NUTX shares at $93.56; stock down 50.1% from high as 3 other insiders also buy

Frank E Jaumot, a Director at Nutex Health, purchased 150 shares at $93.56 on 2026-03-20, establishing an initial position. This purchase occurred within a 14-day window in which 3 other insiders also made open-market buys, establishing a cluster acquisition pattern. The stock currently trades at $94.98, down 50.1% from its 52-week high of $190.49 and down 43.2% over the prior 90 days, while the company reports strong fundamentals: $267.8M in latest quarterly revenue, $55.4M net income, and 82.4% annual revenue growth. The confluence of multiple insiders purchasing near price lows, combined with robust financial metrics, merits monitoring of whether the cluster represents meaningful conviction in valuation or reflects routine scheduled activity.

President Hosseinion Warren buys 252 NUTX shares at $94.07; cluster of 3 other insiders buying within 14 days as stock down 50.1% from 52-week high.

Hosseinion Warren, NUTX President, purchased 252 shares for $23,706.22 on 2026-03-19 at $94.07, adding 3.4% to his holdings as the stock trades $94.98 currently—down 50.1% from its 52-week high of $190.49. The transaction occurs amid a cluster pattern: 3 other insiders also bought within the past 14 days. Company fundamentals show strong revenue growth of 82.4% year-over-year with revenue of $267,804,000.00 and net income of $55,435,000.00, yielding a low P/E of 4.75. The concurrent multi-insider buying activity against the backdrop of significant recent share-price decline and solid earnings performance presents a noteworthy signal of potential management conviction, though the 90-day price decline of 43.2% and 30-day decline of 6.0% warrant scrutiny into catalysts for the recent downturn.

Director Spears Kelvin bought 10 shares of NUTX at $94.46 on 2026-03-17, stock down 50.6% from 52-week high of $190.49.

Director Kelvin Spears purchased 10 shares at $94.46 on 2026-03-17, increasing his holdings from 32,127 to 32,137 shares. The transaction represents a minimal trade of just 10 shares (+0.0% vs pre-transaction holdings), occurring after the stock has declined 50.6% from its 52-week high of $190.49 and 5.7% over the prior 30 days. While NUTX exhibits strong fundamentals with $267.8M in latest quarterly revenue, +82.4% annual growth, and a lean P/E of 4.71, the director's small purchase magnitude and lack of material change to his position offer limited signal regarding his conviction in the equity or near-term outlook.

Chief Legal Officer Montgomery Pamela W. purchases 79 NUTX shares at $88.87; stock down -46.0% in 90 days despite 4.64 P/E and +82.4% annual revenue growth.

Montgomery Pamela W., Chief Legal Officer of Nutex Health Inc., purchased 79 shares at $88.87 on 2026-03-13, increasing her holdings from 2,679 to 2,758 shares. The timing is notable given price momentum: the stock has declined -7.0% over 30 days and -46.0% over 90 days, currently trading at $92.70 against a 52-week high of $190.49. Fundamentally, Nutex reports $267.8M in quarterly revenue, $55.4M in net income, and +82.4% annual revenue growth with a P/E of 4.64—metrics suggesting operational strength relative to valuation. Her own cross-ticker track record shows 1 prior open-market buy with exceptional 90-day outcomes (+7568.1%), and her single prior NUTX purchase in 2023 exhibited similar timing success. The purchase occurs amid material price weakness despite strong underlying financial performance.

CFO Jon Bates buys 750 NUTX shares at $136.71; stock down 35.0% from 52-week high but 90-day pattern shows +37.4% and strong fundamentals (93.8% revenue growth, P/E 6.75)

CFO Jon Christian Bates purchased 750 shares at $136.71 on 2025-11-25, increasing his holdings by 15.3% to 5,638 shares. While the current price of $115.11 is 35.0% below the 52-week high and down 10.0% over 30 days, the stock has risen 37.4% over 90 days, and Bates' prior three purchases at NUTX have shown consistent positive 90-day returns (53.7%, 41.3%, and 7560.0%), all well-timed outcomes where the stock rose after his buys. Fundamentally, NUTX shows strong tailwinds: revenue grew 93.8% year-over-year to $267.8M in the latest quarter, net income stands at $55.4M, and the enterprise trades at a P/E of 6.75, suggesting a valuation disconnect amid significant growth. Bates' pattern of well-timed purchasing decisions at this ticker across a 19-month span (2023–2025), now reinforced by this $102.5K acquisition during a pullback from highs, indicates continued confidence in the name despite recent weakness.

CFO Jon Christian Bates buys 1,000 NUTX shares at $81.81; prior buys at ticker both showed positive 90-day returns (+41.3%, +7560.0%)

CFO Jon Christian Bates purchased 1,000 shares of Nutex Health at $81.81 on 2025-04-08, increasing his holdings to 4,888 shares (+25.7% increase). The stock currently trades at $129.67, representing a gain of approximately 58% from the transaction price. His prior two purchases at NUTX (2024-08-22 and 2023-06-15) both realized positive 90-day returns of +41.3% and +7560.0% respectively, establishing a pattern of well-timed entry points at this ticker. The company is reporting strong revenue growth (+93.8% annually) despite current net losses of $-8.8M on quarterly revenue of $78.8M, suggesting underlying operational challenges even amid top-line expansion. This buy occurs in a stock that has appreciated +305.2% over 90 days and trades near its 52-week high, warranting assessment of whether this reflects conviction in operational turnaround or other factors.

NUTX CFO Bates buys 1,350 shares ($28,969.52) at $21.46; holdings up 145.6%; stock up 208.6% in 30 days

Chief Financial Officer Jon Christian Bates purchased 1,350 shares at $21.46 on 2024-08-22, increasing his holdings from 927 to 2,277 shares—a 145.6% increase in personal position. The purchase comes during extraordinary recent momentum: the stock has surged +208.6% in the past 30 days and +244.8% over 90 days, yet remains -48.5% below its 52-week high of $46.96. Notably, Bates' prior buy at NUTX on 2023-06-15 proved well-timed, delivering 90-day returns of +7560.0%, establishing a demonstrated pattern of trading execution at this ticker. Against this backdrop, the company remains unprofitable (most recent full-year net income was negative), though it posted revenue of $76,082,261.00 with annual growth of +12.9%. The timing and scale of this insider accumulation, combined with his prior track record at this ticker and the stock's explosive recent rally, merits close monitoring of fundamentals and forward guidance.

COO DeTillio bought 1,875 shares ($33,210) at NUTX in 2 transactions; holdings rose 63.9% to 4,808 shares amid +193.1% 30-day rally.

Joshua DeTillio, Chief Operating Officer, executed 2 separate open-market purchases totaling 1,875 shares for $33,210.00 at a blended average price of $17.71 on August 19–20, 2024, expanding his post-transaction holdings to 4,808 shares (a 63.9% increase from 2,933 shares). The timing coincides with an exceptionally volatile period: the stock was at $20.50 as of the filing date, -56.4% from its 52-week high of $46.96, but riding a +193.1% 30-day surge and +177.0% 90-day advance. Notably, DeTillio's prior 2 trades at NUTX (June 2024 and November 2023) both were followed by substantial gains over 30 and 90 days; his June purchase posted +835.2% in 30 days, and his November 2023 purchase returned +11237.6% in 30 days and +6831.6% over 90 days. The company remains unprofitable (latest quarter net income: $-364,048.00) and the market cap is $103.8M, but annual revenue growth was +12.9%. This purchase by a senior operating executive follows a historical pattern of well-executed timing at this specific ticker, though it arrives after an already dramatic price recovery from depressed levels.